Register

Access to new medicines in Europe

Thursday, 01.10.2015 | 16:30 - 19:30

Organised by WHO Regional Office for Europe, National Institute for Health Disability Insurance (NIHDI), Belgium and Main Association of Austrian Social Security Institutions

High-priced medicines. Affordability and sustainable access

The number of new medicines introduced into Europe is increasing, in particular for chronic diseases. National and cross-national medicines policies and strategies are needed to balance demand and expectation for access to high-priced medicines against fiscal responsibility for constrained health budgets.

This forum aims to start the discussion on how to prioritise the introduction of new high-priced medicines, using the area of cancer drugs as an illustrative case study. The forum will also review options for fair pricing to allow availability to all European citizens and affordability for public healthcare systems.

Principles for the appropriate use of medicines and current challenges

Hans Kluge, Director, Health Systems and Public Health, WHO Regional Office for Europe

Medicine prioritisation and new cancer drugs in Europe

Alexandru Eniu, Board Member and Chair of the Emerging Countries Committee, European Society for Medical Oncology (EMSO)

Cancer medicine as a challenge for public pricing and reimbursement

Sabine Vogler, Gesundheit Österreich GmbH, WHO Collaborating Centre for Pharmaceutical Pricing and Reimbursement Policies

Understanding patient-side demand for medicines

Nicola Bedlington, Secretary General, European Patients' Forum

Panel discussion

Josef Probst, Director General, Main Association of Austrian Social Security Institutions

Maria Iglesia, Head of Unit for Healthcare Systems, DG Health and Food Safety (DG SANTE), European Commission

Lieven Annemans, Professor of Health Economics, Ghent University, Belgium

Pascale Boulet, Independent Consultant in Medicines Law and Policy

Susan Spillane, Senior Pharmacist, National Centre for Pharmacoeconomics (NCPE), Ireland | Young Forum Gastein Scholar

Moderation

Jack Scannell, Center for the Advancement of Sustainable Medical innovation (CASMI), University of Oxford, UK

EHFG News & Updates

EHFG Headquarters

EHFG Vienna Office

VAT No. ATU44155007 Bank Data:
IBAN AT 152040400200222240 
BIC SBGSAT2S
Bank Salzburger Sparkasse
Kirchplatz, 5630 Bad Hofgastein, Austria